Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Baloxavir marboxil | Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. Alternative Names: S-033188; HY-109025. CAS No. 1985606-14-1. Pack Sizes: 50 mg. Product ID: B2692-291710. Molecular formula: C27H23F2N3O7S. Mole weight: 571.55. Custom synthesis is available. Send your inquiries for more information. |  London |
| Baloxavir | Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. Alternative Names: Baloxavir acid; BXA; Xofluza; S-033447. CAS No. 1985605-59-1. Pack Sizes: 50 mg. Product ID: B2692-008721. Molecular formula: C24H19F2N3O4S. Mole weight: 483.49. Custom synthesis is available. Send your inquiries for more information. | London |
| Baloxavir-[d4] | Baloxavir-[d4] is an isotope compound of Baloxavir. Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. CAS No. 2415027-80-2. Pack Sizes: 2 mg. Product ID: BLP-003387. Molecular formula: C24H15D4F2N3O4S. Mole weight: 487.51. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
